Summary & Overview
HCPCS J9025: Azacitidine Injection, 1 mg
HCPCS Level II code J9025 designates azacitidine injectable, billed per 1 mg unit. Azacitidine is a widely used hypomethylating agent in oncology, primarily for hematologic malignancies; clear identification of the drug unit is critical for accurate chemotherapy billing, inventory management, and payment processing across outpatient infusion sites nationwide. This code matters nationally because it aligns drug dosing and reimbursement units with clinical administration, affecting hospital outpatient departments, oncology clinics, and payer contracting.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise exposition of clinical context for azacitidine use, typical sites of service for billing, and the practical implications for claims processing. The publication presents national benchmarks where available, summarizes relevant policy and coverage considerations, and outlines billing elements clinicians and revenue-cycle staff should track for accurate claim submission.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, or specific payer rate tables. The content focuses on the code definition, clinical service type, and where this billing code is most commonly encountered in practice.
Billing Code Overview
HCPCS Level II code J9025 represents an injectable oncology agent: azacitidine, 1 mg. This code describes a billed unit of the chemotherapeutic medication azacitidine supplied for parenteral administration.
-
Service type: Injectable chemotherapy/antineoplastic agent
-
Typical site of service: Hospital outpatient department, physician office infusion suite, or other outpatient infusion settings
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related billing details.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 68-year-old with a new diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who presents to an outpatient oncology infusion center for disease-directed therapy. The clinical workflow begins with physician evaluation and order entry for J9025 (azacitidine injection) with the prescribed dose calculated in milligrams based on body surface area or weight. Nursing conducts pre‑infusion assessment including vital signs, complete blood count review, platelet count, and review of concomitant medications. The medication is prepared by pharmacy as a single‑use vial or prefilled syringe for subcutaneous or intravenous administration per the prescriber’s route. Nursing verifies patient identity, consent, and chemotherapy safety checklist, then administers J9025 via subcutaneous injection or intravenous infusion according to the facility protocol. Post‑administration monitoring includes assessment for injection site reactions, hypotension, allergic reaction, and routine lab surveillance in subsequent days. Documentation includes dose in mg, NDC and lot number if required by payor rules, applicable modifier(s) for billing, and the primary ICD‑10 diagnosis supporting medical necessity.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JZ | Drug administered, single unit vial used, no wastage reported |